On 26 June 2026, the Australian Industrial Chemicals Introduction Scheme (the “AICIS”) published its evaluation of retinal, also known as retinaldehyde.

AICIS concluded that retinal meets the criteria for classification as:

The assessment’s conclusion is largely based on retinal’s position in the retinoid metabolic pathway. Retinal is converted into retinoic acid, a well-established teratogen, and is the immediate precursor to retinoic acid. AICIS therefore considers it likely to be more potent than retinol or retinyl esters.

Importantly, the finding is not that cosmetic retinal products cause known birth defects in humans. In fact, the report acknowledges that retinal-specific data are limited and that available human studies on low-concentration topical retinoids have not demonstrated a significant increase in congenital malformations.

It is also important to distinguish hazard from risk. This evaluation considered whether retinal has an inherent developmental toxicity hazard. It did not determine that every cosmetic product containing retinal presents an unacceptable risk at its particular concentration or pattern of use.

However, the regulatory consequences are substantial.

Future introduction may still be possible, but an importer or manufacturer would need to obtain an Assessment Certificate, allowing AICIS to assess the actual exposure, proposed use and risk-management measures.

That means additional government fees, technical documentation, regulatory advice and potentially supporting data before the ingredient can legally be introduced into Australia.

For smaller brands and importers, this is likely to make commercialisation significantly more challenging and may make some retinal products commercially unviable.

Based on the hazard classification, I would expect a retinal application to require at least a Health Focus Assessment, rather than the cheaper “very low to low risk” pathway.

The AICIS retinal evaluation does not explicitly state which assessment type would apply, but it makes clear that an Assessment Certificate is now required for consumer cosmetic uses.

The government fee is only part of the expense. Most brands also need to prepare a technical dossier, gather toxicology data and often engage a regulatory consultant.

• Government fee: approximately AUD $34,760 for a Health Focus Assessment
• Regulatory consultant: approximately AUD $10,000–30,000+
• Additional studies or data acquisition: potentially tens of thousands more, if required

These changes are particularly relevant for the beauty sector because retinal has become increasingly common in Asian skincare, including Korean and Japanese anti-ageing products.

This decision has the potential to affect a significant number of Asian beauty products introduced into Australia, particularly where the Australian importer has relied on the lower-burden Exempted or Reported pathways.

Importantly, this ruling does not make retinal illegal in Australia.

But it does significantly raise the regulatory barrier to entry, particularly for smaller cosmetic brands and importers, many of whom may struggle to justify the cost of an Assessment Certificate.